You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Vorinostat - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for vorinostat and what is the scope of freedom to operate?

Vorinostat is the generic ingredient in one branded drug marketed by Msd Sub Merck and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vorinostat has one hundred and thirty-one patent family members in thirty-five countries.

There are two drug master file entries for vorinostat. One supplier is listed for this compound.

Summary for vorinostat
International Patents:131
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 136
Clinical Trials: 279
Patent Applications: 7,387
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in vorinostat?vorinostat excipients list
DailyMed Link:vorinostat at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vorinostat
Generic Entry Date for vorinostat*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for vorinostat

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AmgenPhase 1/Phase 2
Pediatric Oncology Experimental Therapeutics Investigators' ConsortiumPhase 1/Phase 2
Lucile Packard Children's Hospital FoundationPhase 1/Phase 2

See all vorinostat clinical trials

Pharmacology for vorinostat

US Patents and Regulatory Information for vorinostat

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for vorinostat

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Try a Trial ⤷  Try a Trial
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Try a Trial ⤷  Try a Trial
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Try a Trial ⤷  Try a Trial
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Try a Trial ⤷  Try a Trial
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for vorinostat

Country Patent Number Title Estimated Expiration
Iceland 8357 Aðferð við að meðhöndla krabbamein með HDAC hindrum ⤷  Try a Trial
New Zealand 568678 Methods of inducing terminal differentiation using suberoylanilide hydroxamic acid (SAHA) ⤷  Try a Trial
Portugal 1663194 ⤷  Try a Trial
Japan 2011251985 FORMULATION OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHOD FOR PRODUCING SAME ⤷  Try a Trial
Russian Federation 2530648 СПОСОБЫ ИНДУКЦИИ КОНЕЧНОЙ ДИФФЕРЕНЦИРОВКИ (METHOD OF FINAL DIFFERENTIATION INDUCTION) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.